Watchman FLX Pro heart device study in Europe
Part of Heart & circulation clinical trials.
This study tracks people with atrial fibrillation (an irregular heartbeat) who get the WATCHMAN FLX Pro device to reduce stroke risk. It collects real-world data on how well the device works and how safe it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have atrial fibrillation (irregular heartbeat) not caused by a bad heart valve or a mechanical heart valve.
- Your doctor has decided you need the WATCHMAN FLX Pro device.
- You are 18 or older (or the legal age in your country).
- You are willing to come back for follow-up visits and exams.
- You likely have at least 12 months to live.
- You are not pregnant or planning to become pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people who need both a special heart treatment called pulsed field ablation (FARAPULSE) and a device to close off a small pouch in the heart (WATCHMAN FLX Pro or WATCHMAN FLX) to prevent strokes. The study will see how well both procedures work when done together.
This study tests whether doing a common AFib procedure (radiofrequency ablation) is safe and effective at the same time as closing off the left atrial appendage with the WATCHMAN FLX device. It's for people with nonvalvular atrial fibrillation who are already candidates for both treatments.
This trial tests a new device called LAmbre™ II that closes off a part of the heart called the left atrial appendage to help prevent strokes in people with atrial fibrillation who cannot take blood thinners.
This trial tests a device called LAmbre™ II that is placed in the heart to reduce stroke risk in people with atrial fibrillation who cannot take blood thinners. It may be an option if you need an alternative to long-term blood-thinning medication.
This trial compares a heart device that can help prevent blood clots in the heart (called LAAO) versus long-term blood thinners for people who have atrial fibrillation and recently had a stent placed. It aims to see which approach better prevents stroke and related blood-clot problems while keeping side effects manageable.
This study looks at long-term outcomes after LAA closure (a procedure to reduce stroke risk) by reviewing CT scans of the device. It aims to learn if blood flow around the device affects healing and future health.
Hear when a new Left Atrial Appendage Closure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.